Filing Flows › Angiodynamics (ANGO) › Q1 FY27 › vs Q4 FY26
Angiodynamics (ANGO) Q1 FY27 vs Q4 FY26 (quarter over quarter)
Angiodynamics's revenue fell $5.7M (-7%) from $86.6M in Q4 FY26 to $80.9M in Q1 FY27.
Angiodynamics, Q1 FY27: revenue $80.9M (+7% year over year), operating margin -9.0%, net loss $7.1M, operating cash flow −$15.3M. The chart draws each line against Q4 FY26, the increases inside each band.
Every line
| Line | Q1 FY27 | Q4 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $80.9M | $86.6M | −$5.7M | -7% |
| Income tax benefit | $199K | −$370K | $569K | — |
| Net loss | $7.1M | $11.4M | −$4.3M | -38% |
| Costs & expenses | $88.2M | $98.0M | −$9.8M | -10% |
| Operating costs | $88.2M | $96.8M | −$8.6M | -9% |
| Cost of revenue | $32.9M | $39.8M | −$7.0M | -17% |
| Research & development | $8.0M | $8.2M | −$199K | -2% |
| Sales & marketing | $30.0M | $31.1M | −$1.1M | -4% |
| General & admin | $12.5M | $10.3M | $2.2M | +21% |
| Other operating costs | $4.9M | $7.4M | −$2.5M | -34% |
| Operating cash sources | $25.3M | −$7.9M | $33.3M | — |
| Depreciation & amortization | $5.5M | $5.6M | −$99K | -2% |
| Share-based compensation | $4.5M | $3.9M | $587K | +15% |
| Cash used in operations | $15.3M | −$17.5M | $32.8M | — |
| Net loss absorbed | $7.1M | $11.4M | −$4.3M | -38% |
| Working capital & other | $18.2M | −$19.3M | $37.6M | — |
Questions
How much did Angiodynamics's revenue grow quarter over quarter in Q1 FY27?
Angiodynamics's revenue fell $5.7M (-7%) from $86.6M in Q4 FY26 to $80.9M in Q1 FY27.